KMO and juvenile Huntington disease: For example, the expression in yeast of mutant and wildtype forms of the Huntington's disease gene revealed important factors regulating the toxicity of protein aggregates [11],[15],[19], and a genome-wide suppressor screen in yeast uncovered kynurenine 3-monooxygenase as a potential new therapeutic target for the treatment of Huntington's disease [13].